Lupin launches Rivaroxaban tablets in the US

Lupin Limited [BSE: LUPIN] announced the launch of Rivaroxaban Tablets USP, 2.5 mg, in the United States, effective March 7, 2025. This launch follows the final approval of Lupin's Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration. Rivaroxaban Tablets USP, 2.5 mg, are bioequivalent to Xarelto® and are indicated to reduce the risk of major cardiovascular events in patients with coronary artery disease and major thrombotic vascular events in patients with peripheral artery disease. The estimated annual sales for Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto®) in the U.S. were USD 446 million as of January 2025, according to IQVIA data. The company has 15 manufacturing sites and 7 research centres globally, along with a workforce of over 23,000 professionals.